Clinical Trial Update: A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positvie ctDNA After lead-in Osimertinib Monotherapy [Phase 2]

View source ↗

Summary

A Phase II ctDNA-guided trial evaluating the combination of osimertinib with sacituzumab govitecan in EGFR-mutated advanced non-small cell lung cancer patients …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING